Company Description Savara is a pharmaceutical company developing novel respiratory therapeutics utilizing our proprietary NanoCluster dry powder aerosol drug delivery platform.The aerosols are assembled directly from nanoparticles of an existing therapeutic and delivered via oral pulmonary or nasal routes using off-the-shelf dry powder inhalers.
Proceeds Purposes Savara will use the proceeds from this financing to advance AeroVanc (vancomycin hydrochloride inhalation powder) through a Phase IIa clinical efficacy study.